Fierce Biotech August 23, 2024
Bicara Therapeutics and Zenas Biopharma have provided fresh impetus to the IPO market with filings that illustrate what newly public biotechs may look like in the back half of 2024.
Both companies filed IPO paperwork on Thursday and are yet to say how much they aim to raise. Bicara is seeking money to fund a pivotal phase 2/3 clinical trial of ficerafusp alfa in head and neck squamous cell carcinoma (HNSCC). The biotech plans to use the late-phase data to support a filing for FDA approval of its bifunctional antibody that targets EGFR and TGF-β.
Both targets are clinically validated. EGFR supports cancer cell survival and proliferation. TGF-β promotes immunosuppression in the tumor microenvironment (TME). By binding EGFR on...
Today's Sponsors
Today's Sponsor